Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    C-12-074
Previous Study | Return to List | Next Study

Pharmacokinetics of CLG561 in Patients With Advanced Age-Related Macular Degeneration

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01835015
Recruitment Status : Completed
First Posted : April 18, 2013
Results First Posted : March 25, 2016
Last Update Posted : March 25, 2016
Sponsor:
Information provided by (Responsible Party):
Alcon Research

Brief Summary:
The purpose of this study is to evaluate the safety, tolerability, and serum pharmacokinetics of CLG561 in subjects with advanced age-related macular degeneration (AMD).

Condition or disease Intervention/treatment Phase
Age-related Macular Degeneration Drug: CLG561 Phase 1

Detailed Description:
Subjects were divided into 5 cohorts, with the subjects in each cohort being administered a single IVT dose of CLG561 in 1 of 5 concentration levels A-E, where A=lowest and E=highest. All subjects received active CLG561. Progress from one cohort to the next was time-lagged to allow for safety review. Dosing was also time-lagged within each cohort. Only one eye (designated as the study eye) was dosed per subject. Post-dose safety assessments and ocular examination occurred immediately after the IVT injection and continued throughout the outpatient visits at pre-determined timepoints. Collection of post-injection blood samples began after the IVT injection at pre-determined timepoints. Subjects were followed for up to 84 days.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 50 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: A Multi-Center, Open-Label, Single Ascending Dose Study To Assess the Safety, Tolerability, and Serum Pharmacokinetics of Intravitreal CLG561 in Subjects With Advanced Age-Related Macular Degeneration
Study Start Date : May 2013
Actual Primary Completion Date : November 2014
Actual Study Completion Date : November 2014

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: CLG561, Concentration Level A
Single 50 μL intravitreal injection of CLG561, Dose Level A
Drug: CLG561
Administered by intravitreal injection, Day 1

Experimental: CLG561, Concentration Level B
Single 50 μL intravitreal injection of CLG561, Dose Level B
Drug: CLG561
Administered by intravitreal injection, Day 1

Experimental: CLG561, Concentration Level C
Single 50 μL intravitreal injection of CLG561, Dose Level C
Drug: CLG561
Administered by intravitreal injection, Day 1

Experimental: CLG561, Concentration Level D
Single 50 μL intravitreal injection of CLG561, Dose Level D
Drug: CLG561
Administered by intravitreal injection, Day 1

Experimental: CLG561, Concentration Level E
Single 100 μL intravitreal injection of CLG561, Dose Level E
Drug: CLG561
Administered by intravitreal injection, Day 1




Primary Outcome Measures :
  1. Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) by Visit - Study Eye [ Time Frame: Baseline, Day 2, Day 4, Day 15, Day 29, Day 57, Day 85 ]
    BCVA (with spectacles or other visual corrective devices) using Early Treatment Diabetic Retinopathy Study (ETDRS) testing was reported in letters read correctly. Improvement of BCVA was defined as an increase (gain) in letters read from the baseline assessment. One eye (study eye) contributed to the analysis.

  2. Mean Intra-Ocular Pressure (IOP) by Visit - Study Eye [ Time Frame: Baseline, Day 1, Day 2, Day 4, Day 15, Day 29, Day 57, Day 85 ]
    IOP was measured by Goldmann applanation tonometry or tonopen, at the discretion of the Investigator, and reported in mmHg (millimeters of mercury). A higher IOP can be a greater risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage). One eye (study eye) contributed to the analysis.

  3. Number of Subjects With Change From Normal to Abnormal in Fundus Examination at Any Post-Therapy Visit as Compared to Baseline Assessment [ Time Frame: Baseline, Day 2, Day 4, Day 8, Day 15, Day 29, Day 57, Day 85 ]
    A dilated fundus examination was performed to evaluate the health of the retina, macula, choroid, and optic nerve. Subjects having a normal baseline evaluation were examined at subsequent visits, and any change from normal to abnormal was recorded. Criteria for reclassifying from normal to abnormal were left to the opinion of the investigators. One eye (study eye) contributed to the analysis. None of the abnormalities were deemed related to the study medication.

  4. Number of Subjects With a Change From Normal to Abnormal in Ocular Signs at Any Post-Therapy Visit as Compared to Baseline Assessment [ Time Frame: Baseline, Day 2, Day 4, Day 8, Day 15, Day 29, Day 57, Day 85 ]
    A slit-lamp biomicroscopy examination was performed to evaluate the anterior segment of the eye. Subjects having a normal baseline evaluation were examined at subsequent visits, and any change from normal to abnormal was recorded. Criteria for reclassifying from normal to abnormal were left to the opinion of the investigators. One eye (study eye) contributed to the analysis. None of the abnormalities were deemed related to the study medication.


Secondary Outcome Measures :
  1. Area Under the Serum Concentration-time Curve (AUC) From Time Zero to All [AUC(0-all)] [ Time Frame: Day 1 pre-injection, 2h, 6h, Day 2, Day 4, Day 6, Day 8, Day 11, Day 15, Day 29, Day 57, Day 85 ]
    Serum concentrations at each collection time point were quantitated, where possible, using a validated immunoassay method. These data were analyzed using a noncompartmental pharmacokinetic (PK) method.

  2. Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration [AUC(0-last)] [ Time Frame: Day 1 pre-injection, 2h, 6h, Day 2, Day 4, Day 6, Day 8, Day 11, Day 15, Day 29, Day 57, Day 85 ]
    Serum concentrations at each collection time point were quantitated, where possible, using a validated immunoassay method. These data were analyzed using a noncompartmental PK method.

  3. Time to Reach the Maximum Serum Concentration After Drug Administration (Tmax) [ Time Frame: Day 1 pre-injection, 2h, 6h, Day 2, Day 4, Day 6, Day 8, Day 11, Day 15, Day 29, Day 57, Day 85 ]
    Serum concentrations at each collection time point were quantitated, where possible, using a validated immunoassay method. These data were analyzed using a noncompartmental PK method.

  4. Dose Normalized Observed Maximum Serum Concentration Following Drug Administration (Cmax/D) [ Time Frame: Day 1 pre-injection, 2h, 6h, Day 2, Day 4, Day 6, Day 8, Day 11, Day 15, Day 29, Day 57, Day 85 ]
    Serum concentrations at each collection time point were quantitated, where possible, using a validated immunoassay method. These data were analyzed using a noncompartmental PK method.

  5. Dose-normalized Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration [AUC(0-last)/D] [ Time Frame: Day 1 pre-injection, 2h, 6h, Day 2, Day 4, Day 6, Day 8, Day 11, Day 15, Day 29, Day 57, Day 85 ]
    Serum concentrations at each collection time point were quantitated, where possible, using a validated immunoassay method. These data were analyzed using a noncompartmental PK method.

  6. Area Under the Serum Concentration-time Curve From Time Zero to Time "t" Where t is a Defined Time Point After Administration [AUC(0-t)] [ Time Frame: Day 1 pre-injection, 2h, 6h, Day 2, Day 4, Day 6, Day 8, Day 11, Day 15, Day 29, Day 57, Day 85 ]
    Serum concentrations at each collection time point were quantitated, where possible, using a validated immunoassay method.

  7. Terminal Elimination Half-life (T½) [ Time Frame: Day 1 pre-injection, 2h, 6h, Day 2, Day 4, Day 6, Day 8, Day 11, Day 15, Day 29, Day 57, Day 85 ]
    Serum concentrations at each collection time point were quantitated, where possible, using a validated immunoassay method.

  8. The Apparent Volume of Distribution During the Terminal Elimination Phase Following Extravascular Administration (Vz/F) [ Time Frame: Day 1 pre-injection, 2h, 6h, Day 2, Day 4, Day 6, Day 8, Day 11, Day 15, Day 29, Day 57, Day 85 ]
    Serum concentrations at each collection time point were quantitated, where possible, using a validated immunoassay method.

  9. Apparent Systemic (or Total Body) Clearance From Serum Following Extravascular Administration (CL/F) [ Time Frame: Day 1 pre-injection, 2h, 6h, Day 2, Day 4, Day 6, Day 8, Day 11, Day 15, Day 29, Day 57, Day 85 ]
    Serum concentrations at each collection time point were quantitated, where possible, using a validated immunoassay method.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   55 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of age-related macular degeneration in study eye, as specified in protocol.
  • Poor visual acuity in study eye, as specified in protocol.
  • Willing to receive meningitis and pneumonia vaccinations at least 2 weeks prior to study treatment.
  • Females must be post-menopausal and/or surgically sterile.
  • Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

  • Treatments to the study eye within 28 days prior to study treatment, as specified in protocol.
  • Any disease or medication expected to cause systemic or ocular immunosuppression.
  • Participation in another interventional clinical study or use of any experimental treatment for AMD within 12 weeks prior to study treatment.
  • Other protocol-defined exclusion criteria may apply.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01835015


Sponsors and Collaborators
Alcon Research
Investigators
Layout table for investigator information
Study Director: Head of Clinical Sciences, CA CSI NS/Opth Alcon Research

Layout table for additonal information
Responsible Party: Alcon Research
ClinicalTrials.gov Identifier: NCT01835015     History of Changes
Other Study ID Numbers: C-12-074
First Posted: April 18, 2013    Key Record Dates
Results First Posted: March 25, 2016
Last Update Posted: March 25, 2016
Last Verified: February 2016
Keywords provided by Alcon Research:
First in human
Safety
Tolerability
Serum PK
Intravitreal (IVT)
Age-related macular degeneration
AMD
Geographic Atrophy
Choroidal neovascularization
Additional relevant MeSH terms:
Layout table for MeSH terms
Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases